Supernus Pharmaceuticals (SUPN) Gross Profit (2013 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Gross Profit data on file, last reported at $188.6 million in Q4 2025.

• Gross Profit for Q4 2025 came in at $188.6 million, up 27.36% year-over-year; the trailing twelve-month figure through Dec 2025 was $644.4 million (up 10.36% YoY), and the FY2025 annual result was $644.4 million, up 10.36% from the prior year.
• Gross Profit grew to $188.6 million in Q4 2025 per SUPN's latest filing, from $173.1 million in the prior quarter.
• Over five years, Gross Profit peaked at $188.6 million in Q4 2025 and troughed at $114.5 million in Q2 2023.
• A 5-year average of $141.8 million and a median of $143.2 million in 2021 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2024: Gross Profit dropped 23.48% in 2023, then surged 31.39% in 2024.
• A 5-year view of Gross Profit shows it stood at $142.1 million in 2021, then rose by 1.63% to $144.4 million in 2022, then gained by 0.22% to $144.7 million in 2023, then increased by 2.33% to $148.1 million in 2024, then advanced by 27.36% to $188.6 million in 2025.
• Business Quant data shows SUPN's Gross Profit at $188.6 million in Q4 2025, $173.1 million in Q3 2025, and $148.6 million in Q2 2025.